Put companies on watchlist
PolyPeptide Group
ISIN: CH1110760852
WKN: A3CNHV
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

PolyPeptide Group · ISIN: CH1110760852 · EQS - Company News (39 News)
Country: Switzerland · Primary market: Switzerland · EQS NID: 1606309
12 April 2023 07:18PM

PolyPeptide announces results of the annual General Meeting 2023


PolyPeptide Group / Key word(s): AGMEGM
PolyPeptide announces results of the annual General Meeting 2023

12.04.2023 / 19:18 CET/CEST


Media Release

 

PolyPeptide announces results of the annual General Meeting 2023

 

Baar, 12 April 2023 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleotide-based active pharmaceutical ingredients (the “Company”), today announced that the shareholders approved all proposals put forward by the Board of Directors at the Company’s second annual General Meeting (“AGM 2023”) that took place at the Chollerhalle Zug with a large majority.

The Executive Chairman of the Board of Directors, Peter Wilden, welcomed the shareholders at the Chollerhalle Zug, where a total of 25,522,031 shares with voting rights were represented, corresponding to 77.05% of the issued registered shares of the Company.

All six members of the Board of Directors proposed for re-election and the proposed new independent member of the Board of Directors, Dorothee A. Deuring, were appointed for a term of office ending at the conclusion of the next annual General Meeting 2024. Peter Wilden was re-elected as Chairman of the Board of Directors, and Philippe Weber and Peter Wilden were each individually re-elected as members of the Remuneration and Nomination Committee for a term of office ending at the conclusion of the next annual General Meeting 2024.

Shareholders also approved the Board of Directors’ proposal for the amendments of the Articles of Association implementing, inter alia, the requirements of the revised Swiss corporate law that entered into force on 1 January 2023.

Further proposals of the Board of Directors that were approved at the AGM 2023 included, among others, the re-election of the Independent Proxy and the Statutory Auditors as well as the approval of the maximum aggregate amount of compensation of the Board of Directors and Executive Committee. The shareholders also granted discharge to all members of the Board of Directors and Executive Committee for their activities in the financial year 2022 and approved the Annual Report, Statutory Financial Statements and Consolidated Financial Statements, in each case, for the financial year 2022 as well as the Remuneration Report 2022 in a separate consultative vote.

The minutes of the AGM 2023 will be available within 15 days on the Company’s website. The next annual General Meeting 2024 will be held on 10 April 2024.

 

 

Contact
PolyPeptide Group AG
Michael Stäheli
Head of Investor Relations & Corporate Communications
michael.staeheli@polypeptide.com
T: +41 43 502 0580
 

About PolyPeptide

PolyPeptide Group AG and its consolidated subsidiaries (“PolyPeptide”) is a focused Contract Development & Manufacturing Organization (CDMO) for peptide- and oligonucleotide-based active pharmaceutical ingredients. By supporting its customers mainly in pharma and biotech, it contributes to the health of millions of patients across the world. PolyPeptide offers products and services from pre-clinical through to commercial stages, including generics. Its active custom projects pipeline reflects the opportunities from novel drug therapies in development to fight both widespread and rare diseases. Dating back to 1952, PolyPeptide today runs a global network of six cGMP-certified facilities in Europe, the U.S. and India. PolyPeptide’s shares (SIX: PPGN) are listed on SIX Swiss Exchange. For more information, please visit polypeptide.com.              

@PolyPeptide – follow us on LinkedIn

 

Disclaimer

This media release has been prepared by PolyPeptide Group AG and contains certain forward-looking statements that reflect the current views of management. Such statements are subject to known and unknown risks, uncertainties and other factors that may cause actual developments to differ materially from those expressed or implied in this release. PolyPeptide Group AG is providing the information in this release as of this date and, except as required by applicable laws or regulations, does not undertake any obligation to update any statements contained in it as a result of new information, future events or otherwise.

 

 


Additional features:

File: PolyPeptide_AGM 2023_Publication of results


End of Media Release


Language: English
Company: PolyPeptide Group
Neuhofstrasse 24
6340 Baar
Switzerland
Phone: +41435020580
E-mail: mediateam@polypeptide.com
Internet: www.polypeptide.com
ISIN: CH1110760852
Valor: 111076085
Listed: SIX Swiss Exchange
EQS News ID: 1606309

 
End of News EQS News Service

1606309  12.04.2023 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1606309&application_name=news&site_id=boersengefluester_html
Visual performance / price development - PolyPeptide Group
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.